<DOC>
	<DOCNO>NCT03027739</DOCNO>
	<brief_summary>CART-19 cell emerge powerful targeted immunotherapy , show striking response highly refractory CD19+ acute lymphoblastic leukemia ( ALL ) . This study aim assess safety toxicity CART-19 cell patient refractory high risk relapse define MRD+ status .</brief_summary>
	<brief_title>CART-19 Cells For MRD Positive CD19+ ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Signed write informed consent Aged 160 year Patients MRD positive CD19+ ALL Cardiac : Left ventricular ejection fraction ≥ 50 % Adequate renal hepatic function Performance status : Karnofsky ≥ 70 % Pregnant lactating female . Any comorbidity preclude administration CART19 cell .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>